Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial

JAMA : the Journal of the American Medical Association
Yaling HanBRIGHT Investigators

Abstract

The safety and efficacy of bivalirudin compared with heparin with or without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI) are uncertain. To determine if bivalirudin is superior to heparin alone and to heparin plus tirofiban during primary PCI. Multicenter, open-label trial involving 2194 patients with AMI undergoing primary PCI at 82 centers in China between August 2012 and June 2013. Patients were randomly assigned to receive bivalirudin with a post-PCI infusion (n = 735), heparin alone (n = 729), or heparin plus tirofiban with a post-PCI infusion (n = 730). Among patients treated with bivalirudin, a postprocedure 1.75 mg/kg/h infusion was administered for a median of 180 minutes (IQR, 148-240 minutes). The primary end point was 30-day net adverse clinical events, a composite of major adverse cardiac or cerebral events (all-cause death, reinfarction, ischemia-driven target vessel revascularization, or stroke) or bleeding. Additional prespecified safety end points included the rates of acquired thrombocytopenia at 30 days, and stent thrombosis at 30 days and 1 year. Net adverse clinical events at 30 days occurred in 65 patients (8...Continue Reading

Citations

Nov 9, 2015·Lancet·Freek W A Verheugt
Jul 4, 2015·Expert Review of Cardiovascular Therapy·Thomas A Mavrakanas, Yiannis S Chatzizisis
Feb 18, 2016·Chinese Medical Journal·Chun-Song Hu, Tengiz Tkebuchava
Jan 30, 2016·Journal of Interventional Cardiology·Tim KinnairdRichard Anderson
Jan 21, 2016·The New England Journal of Medicine·Andrzej SurdackiJacek Bednarek
Feb 26, 2016·European Heart Journal·Petr Widimský
Jan 15, 2016·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Zhenyang LiangYaling Han
Mar 5, 2016·Drugs & Aging·Bianca Rocca, Steen Husted
Oct 20, 2015·Journal of the American College of Cardiology·George D DangasUNKNOWN BRAVO-3 Investigators
Jan 23, 2016·Expert Opinion on Pharmacotherapy·Giuseppe GargiuloMarco Valgimigli
Mar 8, 2016·European Heart Journal·Uwe ZeymerGilles Montalescot
Mar 2, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·María Asunción Esteve-PastorFrancisco Marín
Aug 12, 2015·Progress in Cardiovascular Diseases·Jaya Chandrasekhar, Roxana Mehran
Oct 6, 2015·International Journal of Cardiology·Jussi MikkelssonPasi P Karjalainen
Feb 27, 2016·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·William B Hillegass
Feb 27, 2016·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Yusuf Bader, Carey Kimmelstiel
Jun 13, 2015·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Zaher FanariWilliam S Weintraub
Sep 2, 2015·The New England Journal of Medicine·Marco ValgimigliUNKNOWN MATRIX Investigators
Apr 17, 2015·Cardiovascular Therapeutics·Ahmed MahmoudIslam Y Elgendy
Aug 28, 2015·BMC Cardiovascular Disorders·Yuan-hui LiuNing Tan
Jun 22, 2015·American Heart Journal·Dimitrios AlexopoulosGregg W Stone
Apr 11, 2015·Pharmacology & Therapeutics·Thomas A Mavrakanas, Yiannis S Chatzizisis
May 21, 2016·Revista Española De Cardiología·Monica VerdoiaGiuseppe De Luca
Jun 3, 2016·Clinical Medicine : Journal of the Royal College of Physicians of London·Tawfiq ChoudhuryMagdi El-Omar
Jun 25, 2016·Current Treatment Options in Cardiovascular Medicine·Jad RaffoulAndrew J P Klein
Jun 29, 2016·Revista Española De Cardiología·Giuseppe Gargiulo, Marco Valgimigli
Aug 10, 2016·Lancet·Grant W ReedChristopher P Cannon
Jun 5, 2016·Journal of Cardiovascular Pharmacology·José Domingo Cascón-PérezJuan Antonio Castillo-Moreno
Oct 19, 2016·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Mikkel M SchoosGregg W Stone
Nov 21, 2016·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Golnaz SadjadiehLene Holmvang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.